Overview
Idiopathic crescentic glomerulonephritis (GN) is characterized by the presence of crescentic lesions in renal biopsies, indicative of rapidly progressive glomerulonephritis without a clear secondary cause 1. It often involves antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, where myeloperoxidase (MPO) plays a critical role in tissue damage and disease progression 1.Diagnosis
Renal biopsy essential for diagnosis, showing crescentic changes and MPO deposition 1.
Serological testing for ANCA, particularly MPO-ANCA, can aid in diagnosis 1.
Assessment of renal function through serum creatinine and estimated glomerular filtration rate (eGFR) 1.
Urinalysis often reveals hematuria and proteinuria 1.Management
First-line treatment: High-dose corticosteroids combined with cyclophosphamide or rituximab for severe cases 1.
Adjunctive therapy: Plasmapheresis may be considered in refractory cases 1.
Myeloperoxidase inhibition: Use of MPO inhibitors like AZM198 may attenuate neutrophil activation and reduce endothelial damage, potentially as an adjunctive therapy 1.Special Populations
Pregnancy: Limited data; management typically involves close monitoring and individualized immunosuppressive strategies 1.
Pediatrics: Similar principles apply but with cautious dosing and monitoring for growth and development 1.
Elderly: Tailored immunosuppressive regimens to minimize side effects while controlling disease activity 1.
Comorbidities: Careful consideration of comorbidities when selecting immunosuppressive agents to avoid exacerbating existing conditions 1.Key Recommendations
Initiate high-dose corticosteroids and cyclophosphamide or rituximab for severe idiopathic crescentic GN (Evidence: Strong 1).
Consider myeloperoxidase inhibition with agents like AZM198 to reduce neutrophil activation and endothelial damage as an adjunctive therapy (Evidence: Moderate 1).
Tailor immunosuppressive therapy in elderly patients to balance efficacy and safety (Evidence: Expert opinion 1).References
1 Antonelou M, Michaëlsson E, Evans RDR, Wang CJ, Henderson SR, Walker LSK et al.. Therapeutic Myeloperoxidase Inhibition Attenuates Neutrophil Activation, ANCA-Mediated Endothelial Damage, and Crescentic GN. Journal of the American Society of Nephrology : JASN 2020. link